Not yet recruiting NCT07678320
AI Technologies for Enhanced and Celerated High-Field WB-MRI
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Whole Body Imaging, Prostate, MRI, Lung. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Single-center, cross-sectional observational study assessing the feasibility of advanced accelerated MRI sequences versus standard ones in terms of image quality, diagnostic reliability, and acquisition time.
Primary outcome measures
- Image quality [Time frame: 30 months]
Secondary outcome measures (1)
- Image quality - subjective [Time frame: 30-36 months]
Eligibility criteria
Inclusion criteria
- Consecutive adults (≥18 y.o.) admitted to the UO for W MRI for screening procedure.
- Consecutive adult male patients (≥18 y.o.) admitted to the UO for WB-MRI for screening procedure and focus on prostate.
Exclusion criteria
- refused to consent
- claustrophobia
- metal prosthesis potentially affecting image quality
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Kim BK, Kim JS, Lee HJ, Lee JK, Lee HA, Pak S. Low- Versus High-Concentration Iodine Contrast for Hepatic Multiphase CT in Chronic Liver Disease: Image Quality, Lesion Detectability, and Iodine Load Reduction with Modern MDCT-A Retrospective Non-Inferiority Study. Diagnostics (Basel). 2025 Nov 27;15(23):3026. doi: 10.3390/diagnostics15233026. PMID 41374407
- Breit HC, Vosshenrich J, Hofmann V, Rusche T, Kovacs BK, Bach M, Manneck S, Harder D. Image Quality of Lumbar Spine Imaging at 0.55T Low-Field MRI is Comparable to Conventional 1.5T MRI - Initial Observations in Healthy Volunteers. Acad Radiol. 2023 Nov;30(11):2440-2446. doi: 10.1016/j.acra.2023.01.037. Epub 2023 Feb 24. PMID 36841743
- Haller S, Hedderich D, Federau C, Weisstanner C, Edjlali M, Cauter SV, Zaharchuk G. The Current Status of AI-accelerated MRI Techniques in Clinical Use. Radiology. 2025 Nov;317(2):e243819. doi: 10.1148/radiol.243819. PMID 41186470
- Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023 Jul 5;136(13):1583-1590. doi: 10.1097/CM9.0000000000002529. PMID 37027426
- Rata M, Blackledge M, Scurr E, Winfield J, Koh DM, Dragan A, Candito A, King A, Rennie W, Gaba S, Suresh P, Malcolm P, Davis A, Nilak A, Shah A, Gandhi S, Albrizio M, Drury A, Roberts S, Jenner M, Brown S, Kaiser M, Messiou C. Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma. Insights Imaging. 2022 Jul 28;13(1):123. doi: 10 PMID 35900614
- Petralia G, Koh DM, Attariwala R, Busch JJ, Eeles R, Karow D, Lo GG, Messiou C, Sala E, Vargas HA, Zugni F, Padhani AR. Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. Radiology. 2021 Jun;299(3):494-507. doi: 10.1148/radiol.2021201740. Epub 2021 Apr 27. PMID 33904776
Identifiers
NCT: NCT07678320 · AITECH-MRI